Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: Treatment rationale and protocol dynamics of the AvaALL (MO22097) trial

Clinical Lung Cancer

Volumn 12, Issue 6, 2011, Pages 407-411

  Gridelli, Cesare ^a   Bennouna, Jaafar ^b   De Castro, Javier ^c   Dingemans, Anne Marie C ^d   Griesinger, Frank ^e   Grossi, Francesco ^f   Rossi, Antonio ^a   Thatcher, Nick ^g   Wong, Elaine K ^h   Langer, Corey ⁱ  

^a S G MOSCATI HOSPITAL   (Italy)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PIUS HOSPITAL   (Germany)

^f UNIVERSITY OF GENOA   (Italy)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Continued treatment; Metastatic recurrent NSCLC; Randomized clinical trial; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; DOCETAXEL; ERLOTINIB; PEMETREXED; PLATINUM DERIVATIVE;

ADVANCED CANCER; ARTICLE; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL PROTOCOL; CORRELATION ANALYSIS; DRUG CHOICE; DRUG SAFETY; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; INTERNATIONAL AGENCIES; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLATINUM; QUALITY OF LIFE; QUINAZOLINES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80155141305     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.05.002     Document Type: Article

References (27)

1. H.M. Verheul, and H.M. Pinedo The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF Receptor kinase inhibitors Clin Breast Cancer 1 1 suppl 2000 S80 S84
2. H.P. Gerber, and N. Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 2005 671 680 (Pubitemid 40216420)
3. D. Mukhopadhyay, and K. Datta Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors Semin Cancer Biol 14 2004 123 130 (Pubitemid 38234754)
4. J. Folkman V.T. DeVita, S.M.D. Hellman, S.A. Rosenberg, Cancer: Principles and Practice of Oncology 7th ed. 2005 Lippincott Williams & Wilkins Philadelphia 2865 2882
5. R.K. Jain, D.G. Duda, and J.W. Clark Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 2006 24 40 (Pubitemid 43108832)
6. J. Folkman What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1990 4 6 (Pubitemid 20020880)
7. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
8. D.J. Hicklin, and L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1011 1027 (Pubitemid 46202320)
9. P. Baluk, H. Hashizume, and D.M. McDonald Cellular abnormalities of blood vessels as targets in cancer Curr Opin Genet Dev 15 2005 102 111 (Pubitemid 40127638)
10. S. Vosseler, M. Mirancea, and P. Bohlen Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants Cancer Res 65 2005 1294 1305 (Pubitemid 40270156)
11. A. Bagri, H. Kouros-Mehr, and K.G. Leong Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale Trends Mol Med 16 2010 122 132
12. D. Miles, N. Harbeck, and B. Escudier Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials J Clin Oncol 29 2011 83 88
13. M.A. Socinski, R. Crowell, and T.E. Hensing Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition) Chest 132 3 suppl 2007 277S 289S (Pubitemid 47502813)
14. C.G. Azzoli, S. Baker Jr, and S. Temin American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6266
15. G. D'Addario, M. Fruh, and M. Reck Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21 suppl 5 2010 v116 v119
16. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
17. Avastin® treatment information for healthcare professionals Avastin® (bevacizumab) http://www.avastin.com/avastin/hcp/index.m Accessed: December 5, 2010
18. D.H. Johnson, L. Fehrenbacher, and W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191 (Pubitemid 41095154)
19. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
20. A.B. Sandler, G. Kong, and D. Strickland Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer (NSCLC) J Thorac Oncol 5 2010 1416 1423
21. M. Reck, J. von Pawel, and P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAil J Clin Oncol 27 2009 1227 1234
22. M. Reck, J. von Pawel, and P. Zatloukal Overall survival with cisplatin/gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small cell lung cancer: results from a randomized phase III trial (AVAiL) Ann Oncol 21 2010 1804 1809
23. L. Crin, E. Dansin, and P. Garrido Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study Lancet Oncol 11 2010 733 740
24. A.J. Wozniak, J. Garst, and M. Jahanzeb Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS) J Clin Oncol 28 15 suppl 2010 567s (abstract 7618)
25. A. Grothey, M.M. Sugrue, and D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
26. B. Bergman, N.K. Aaronson, and S. Ahmedzai The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QoL-C30) for use in lung cancer clinical trials EORTC Study Group on Quality of Life Eur J Cancer 30A 1994 635 642 (Pubitemid 24164250)
27. K.K.G. Lan, and D.L. DeMets Discrete sequential boundaries for clinical trials Biometrika 70 1983 659 663